Vericel (VCEL) Change in Receivables (2010 - 2026)
Vericel (VCEL) posted Change in Receivables of $3.3 million for Q2 2026, up 127.17% sequentially from -$12.3 million in Q1 2026, and down 70.78% YoY from $11.4 million in Q2 2025.
Vericel (VCEL) Change in Receivables (2010 - 2026) Analysis & Trends
Vericel has reported Change in Receivables for 16 years, with the latest figure at $3.3 million in Q2 2026.
- Quarterly Change in Receivables fell 70.78% year-over-year to $3.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $11.4 million (down 29.9% YoY) and the FY2025 annual result came in at $23.3 million, up 670.42% from the prior year.
- Change in Receivables advanced to $3.3 million in Q2 2026 per VCEL's latest filing, from -$12.3 million in the prior quarter.
- Over five years, Change in Receivables peaked at $24.2 million in Q4 2025 and troughed at -$12.3 million in Q1 2026.
- A 5-year average of $2.1 million and a median of $557500.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables sank 4745.0% in 2024, then jumped 687.77% in 2025.
- Over 5 years, Change in Receivables stood at $12.2 million in 2022, then soared by 52.14% to $18.6 million in 2023, then slumped by 30.77% to $12.9 million in 2024, then soared by 87.72% to $24.2 million in 2025, then tumbled by 86.25% to $3.3 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $3.3 million, -$12.3 million, and $24.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 3.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.33 Mn |
| Jun 30, 2026 | 3.33 Mn |
| Mar 31, 2026 | -12.25 Mn |
| Mar 31, 2026 | -12.25 Mn |
| Dec 31, 2025 | 24.21 Mn |
| Dec 31, 2025 | 24.21 Mn |
| Sep 30, 2025 | -3.86 Mn |
| Sep 30, 2025 | -3.86 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Sep 30, 2024 | 483,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Mar 31, 2024 | -8.42 Mn |